Barrons

In: Finance

JHVEPhoto Barron’s said this week that ResMed (NYSE:RMD) trades at a compelling valuation after the stock sold off last month in reaction to positive data for Eli Lilly’s (NYSE:LLY) GLP-1 therapy, tirzepatide, in obstructive sleep apnea, a condition targeted by the MedTech company. In late June, Lilly (LLY) said tirzepatide,Continue Reading

In: Finance

fredrocko/iStock Unreleased via Getty Images Barron’s issued a positive commentary on Ford Motor (NYSE:F) in its latest edition, noting that despite a sharp underperformance this year, the Dearborn, Michigan-based automaker is ready to close the gap with its Detroit rival General Motors (NYSE:GM). Ford (F) has gained only ~7% YTD,Continue Reading